Make faster, better drug development decisions
Investment and interest into microbiome-based therapeutics has been growing substantially in the past year – given the recent announcement of pivotal results, the field is inching closer to its first approval. With increases in the number of clinical trials and research programs exploring new disease indications and leveraging novel microbiome-based technologies, the field will become more complex, making it a huge challenge for companies to stay abreast of the latest developments in the field.
Beacon Microbiome provides drug developers with detailed views of the expanding microbiome landscape.
Beacon Microbiome
Track the microbiome clinical trial and drug landscape with Beacon Microbiome
What we cover
Beacon Microbiome covers all pharmaceutical grade microbiome-based therapeutics across all disease indications. The database includes:
- Live biotherapeutics
- Whole ecosystem derived products
- Inactivated microbes
- Bacteriophages
- Microbiome targeting molecules
- Microbiome sourced molecules
All nutraceuticals, dietary supplements, medical foods and diagnostics are excluded.
New data expansion: Deals and Companies. Gain unparalleled access to in-depth company profiles and the latest commercial deals. Monitor your competitors and opportunities as well as benchmark deals and evaluate potential partners. Learn more about Deals and Companies data by downloading the factsheet.
How Beacon helps
Here are some examples of how Beacon Microbiome can accelerate your research programs:
- Search for microbiome drugs across all stages of development so you can stay on top of new approaches in drug design.
- Drastically reduce manual research time with our database solution which allows you to rapidly navigate data for analysis based on microbiome targets, species, therapy type and much more.
- Real-time updates to help you keep track of new players, new assets and entries into the clinic which is vital in such a rapidly developing field.
How Beacon Microbiome works
Search the trial and drug landscape by microbial species, target factor and therapy type, alongside other search criteria to instantly extract the data points you need to conduct more complex analyses.
Our unique Milestones filter and visualization highlights past, present, and future drug development milestones including drug and trial readouts, asset history, and regulatory announcements. This enhancement provides an accurate, timely and exhaustive single-drug timeline allowing you to benchmark progress in the microbiome space.
How we target the data
We house all publicly available sources of data updated within 24 – 48 hours of publication proactively. Our sources cover (but are not limited to):
- Clinical trials registries
- Scientific journals and publications
- Company reports and presentations
- Press releases
- Conference reports and abstracts
- Government and regulatory organizations
- Newspapers and other media
- Patents
Related Content
H1 2024 Microbiome Landscape Review
Investment Trends in Early-Stage Biopharma: A Beacon Data Perspective
Microbiome: US Market and LBP Development
What our customers say
Beacon is a great database that people should pay attention to. It's much better than many of the more generic databases that try to capture all data about everything
Director
Top Biotech Company
Our Microbiome Expert
Ada Lam is the lead research analyst for Beacon Microbiome.
Sign up for our weekly newsletter to uncover the latest insights into the Microbiome landscape using data from Beacon.
Other Beacon Solutions
Covering all Antibody Drug Conjugates (ADCs), Small Molecule Drug Conjugates (SMDCs), Protein Drug Conjugates (PDCs), Immunotoxins and more
Covering all Bi- and Multi-Specific Antibodies, Antibody Fragments, Augmented Antibodies and more
Beacon Cancer Vaccine provides the solution you need to master the prophylactic and therapeutic cancer vaccines field.
Covering all engineered and non-engineered immune cell therapies, including CAR-T, TCR, NK, TILs, Gamma-Delta T Cells and more
Covering all Immune Checkpoint Combination Trials and Immune Checkpoint Modulators in development across 27 different checkpoint targets
Covering all cytokines and drugs that target a cytokine or its immediate receptor belonging to the Interleukins, Interferons, Colony-stimulating factors, Transforming growth factor β, Tumour necrosis factor and Chemokines families.
Beacon DDR steps into the field to give drug developers the precise detailed view and broader picture of what is truly happening in the DDR field.
Covering all therapeutics aimed at treating immune-mediated diseases – Beacon Immune Tolerance provides drug developers with detailed views of the expanding immune tolerance landscape.
From gene-editing technologies, novel delivery systems, and a variety of genetic materials being used- Beacon Gene Therapy steps into the field to give drug developers a precise and detailed view of how the gene therapy landscape looks.
From capturing viral family and strains to understanding any genetic modifications – Beacon Oncolytic Viruses steps into the field to give drug developers the precise detailed view and broader picture of what is truly happening in the Oncolytic Virus field.
Covering Oligonucleotide-based, mRNA-Based, Ribozyme, and gRNA-Mediated Gene Editing therapies, as well as RNA-Targeted Small Molecules – Beacon RNA covers all disease indications and many modalities to provide a detailed landscape of the RNA space.
Beacon TPD provides the solution you need to master the targeted protein degradation field.
Any questions? Contact us
To learn more about how we can tailor Beacon Microbiome to help you, get in touch with our sales team
About Beacon
We are a clinical trial and pipeline database solution, designed in partnership with pharmaceutical professionals. We track targeted therapies to provide accurate, in-depth and real-time information in the rapidly evolving landscape of drug development.
